三种氨基水杨酸制剂治疗溃疡性结肠炎的安全性和有效性研究

Study on the safety and efficacy of three amino salicylc acid preparations for treating ulcerative colitis

目的观察美沙拉嗪、奥沙拉嗪和柳氮磺吡啶治疗溃疡性结肠炎的临床疗效和不良反应。方法选择120例轻中度溃疡性结肠炎患者,随机分为美沙拉嗪组(n=40)、奥沙拉嗪组(n=39)和柳氮磺吡啶组(n=41),分别接受上述三种药物治疗。美沙拉嗪组和奥沙拉嗪组患者口服药物剂量均为每次1.0g,每日3次;而柳氮磺吡啶组患者服用剂量为每次1.0g,每日4次。治疗12周后观察治疗疗效和不良反应发生情况。结果美沙拉嗪组、奥沙拉嗪组和柳氮磺吡啶组临床有效率分别为30.0%、28.2%和51.2%,总有效率分别为75.0%、76.9%和92.7%。柳氮磺吡啶组疗效优于美沙拉嗪组、奥沙拉嗪组(P<0.05)。结论与美沙拉嗪、奥沙拉嗪相比,柳氮磺吡啶治疗溃疡性结肠炎有效性更高,但不良反应发生率稍高。

Objective To evaluate the therapeutic effects of mesalazine, osalazine and sulfasalazine for patientswith ulcerative colitis. Methods 120 patients with ulcerative colitis were randomly divided into mesalazinegroup（n=40）, osalazine group（n=39） and sulfasalazine group（n=41）. The efficacy and adverse events of the three groups were observed after the treatment of 12 weeks. Results The rate of complete remission and overall effective rate of three groupswere30.0%, 28.2% and 51.2%; 75.0%, 76.9% and 92.7%, respectively. And the differences between mesalazine/osalazine and sulfasalazine were statistically significant （P 〈 0.05）. Conclusion Compared with mesalazine and osalazine, sulfasalazine is more effective in treatment of ulcerative colitis, but with a relatively higher incidence of adverse reactions.